Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead Hyloris Pharmaceuticals SAAugust 4, 2021 GMT On target to grow the broad product pipeline with at least 3 additional programmes before end 2021 Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end €53.47 million in cash and cash equivalents to execute ambitious growth ...